Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 07 10 2020
accepted: 04 02 2021
entrez: 15 3 2021
pubmed: 16 3 2021
medline: 7 7 2021
Statut: epublish

Résumé

It is unclear whether insulin resistance (IR) contributes to excess mortality in patients with type 2 diabetes independent of diabetic kidney disease (DKD), which is strongly associated with IR and is a major risk factor for cardiovascular disease (CVD), the main cause of death in these individuals. We tested this hypothesis in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events Italian Multicentre Study. This observational, prospective, cohort study enrolled 15,773 patients with type 2 diabetes attending 19 Italian Diabetes Clinics in 2006-2008. Insulin sensitivity was assessed as estimated glucose disposal rate (eGDR), which was validated against the euglycaemic-hyperinsulinemic clamp technique. Vital status on October 31, 2015, was retrieved for 15,656 patients (99.3%). Participants were stratified by eGDR tertiles from T1 (≥ 5.35 mg/kg/min) to T3 (≤ 4.14 mg/kg/min, highest IR). CVD risk profile was worse in T2 and T3 vs T1. eGDR tertiles were independently associated with micro- and macroalbuminuria and the albuminuric DKD phenotypes (albuminuria with preserved or reduced estimated glomerular filtration rate [eGFR]) as well as with eGFR categories or the nonalbuminuric DKD phenotype. Over a 7.4-year follow-up, unadjusted death rates and mortality risks increased progressively across eGDR tertiles, but remained significantly elevated after adjustment only in T3 vs T1 (age- and gender- adjusted death rate, 22.35 vs 16.74 per 1000 person-years, p < 0.0001, and hazard ratio [HR] adjusted for multiple confounders including DKD, 1.140 [95% confidence interval [CI], 1.049-1.238], p = 0.002). However, eGDR was independently associated with mortality in participants with no DKD (adjusted HR, 1.214 [95% CI, 1.072-1.375], p = 0.002) and in those with nonalbuminuric DKD (1.276 [1.034-1.575], p = 0.023), but not in those with the albuminuric DKD phenotypes. Moreover, the association was stronger in males and in younger individuals and was observed in those without but not with prior CVD, though interaction was significant only for age. The proxy of insulin sensitivity eGDR predicts all-cause mortality in type 2 diabetes, independent of confounders including DKD. However, the impact of IR in individuals with albuminuric DKD may be mediated by its relationship with albuminuria. ClinicalTrials.gov , NCT00715481, retrospectively registered 15 July 2008.

Sections du résumé

BACKGROUND
It is unclear whether insulin resistance (IR) contributes to excess mortality in patients with type 2 diabetes independent of diabetic kidney disease (DKD), which is strongly associated with IR and is a major risk factor for cardiovascular disease (CVD), the main cause of death in these individuals. We tested this hypothesis in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events Italian Multicentre Study.
METHODS
This observational, prospective, cohort study enrolled 15,773 patients with type 2 diabetes attending 19 Italian Diabetes Clinics in 2006-2008. Insulin sensitivity was assessed as estimated glucose disposal rate (eGDR), which was validated against the euglycaemic-hyperinsulinemic clamp technique. Vital status on October 31, 2015, was retrieved for 15,656 patients (99.3%). Participants were stratified by eGDR tertiles from T1 (≥ 5.35 mg/kg/min) to T3 (≤ 4.14 mg/kg/min, highest IR).
RESULTS
CVD risk profile was worse in T2 and T3 vs T1. eGDR tertiles were independently associated with micro- and macroalbuminuria and the albuminuric DKD phenotypes (albuminuria with preserved or reduced estimated glomerular filtration rate [eGFR]) as well as with eGFR categories or the nonalbuminuric DKD phenotype. Over a 7.4-year follow-up, unadjusted death rates and mortality risks increased progressively across eGDR tertiles, but remained significantly elevated after adjustment only in T3 vs T1 (age- and gender- adjusted death rate, 22.35 vs 16.74 per 1000 person-years, p < 0.0001, and hazard ratio [HR] adjusted for multiple confounders including DKD, 1.140 [95% confidence interval [CI], 1.049-1.238], p = 0.002). However, eGDR was independently associated with mortality in participants with no DKD (adjusted HR, 1.214 [95% CI, 1.072-1.375], p = 0.002) and in those with nonalbuminuric DKD (1.276 [1.034-1.575], p = 0.023), but not in those with the albuminuric DKD phenotypes. Moreover, the association was stronger in males and in younger individuals and was observed in those without but not with prior CVD, though interaction was significant only for age.
CONCLUSIONS
The proxy of insulin sensitivity eGDR predicts all-cause mortality in type 2 diabetes, independent of confounders including DKD. However, the impact of IR in individuals with albuminuric DKD may be mediated by its relationship with albuminuria.
TRIAL REGISTRATION
ClinicalTrials.gov , NCT00715481, retrospectively registered 15 July 2008.

Identifiants

pubmed: 33715620
doi: 10.1186/s12916-021-01936-3
pii: 10.1186/s12916-021-01936-3
pmc: PMC7962330
doi:

Banques de données

ClinicalTrials.gov
['NCT00715481']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

66

Investigateurs

Giuseppe Pugliese (G)
Giuseppe Penno (G)
Anna Solini (A)
Enzo Bonora (E)
Emanuela Orsi (E)
Roberto Trevisan (R)
Luigi Laviola (L)
Antonio Nicolucci (A)

Références

Diabetes Care. 2012 Jan;35(1):143-9
pubmed: 22124714
Diabetes Care. 2012 Nov;35(11):2317-23
pubmed: 23093684
Diabetes Care. 2010 Jun;33(6):1179-85
pubmed: 20200308
Diabetes Care. 2014 Jun;37(6):1597-603
pubmed: 24623021
Heart Fail Rev. 2016 Jan;21(1):11-23
pubmed: 26542377
J Intern Med. 2013 Aug;274(2):176-91
pubmed: 23565931
Metabolism. 2018 Apr;81:52-62
pubmed: 29191456
Heart Vessels. 2017 Mar;32(3):269-278
pubmed: 27401741
Diabetes Care. 2003 May;26(5):1374-9
pubmed: 12716791
Kidney Int. 2002 Sep;62(3):963-70
pubmed: 12164879
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Diabetologia. 2016 Nov;59(11):2298-2307
pubmed: 27531506
J Hypertens. 2011 Sep;29(9):1802-9
pubmed: 21738053
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1087-F1108
pubmed: 27707707
Diabetologia. 2010 Jan;53(1):79-88
pubmed: 19894029
Ann Epidemiol. 2002 Jul;12(5):331-7
pubmed: 12062921
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Diabetes. 2000 Apr;49(4):626-32
pubmed: 10871201
Acta Diabetol. 2018 Jun;55(6):603-612
pubmed: 29574497
N Engl J Med. 2017 Apr 13;376(15):1407-1418
pubmed: 28402770
Hypertension. 2014 Dec;64(6):1299-305
pubmed: 25225211
Diabetes Care. 2013 Aug;36(8):2280-5
pubmed: 23596179
Diabetes Care. 2020 Oct;43(10):e139-e141
pubmed: 32796028
Atherosclerosis. 2014 Aug;235(2):538-45
pubmed: 24956526
Diabetes Care. 2012 Jun;35(6):1355-60
pubmed: 22432118
Diabetologia. 2014 Dec;57(12):2513-20
pubmed: 25264116
BMC Nephrol. 2019 Feb 20;20(1):60
pubmed: 30786864
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Diabetes Obes Metab. 2018 Mar;20(3):556-563
pubmed: 28884949
Lancet. 2018 Jun 16;391(10138):2430-2440
pubmed: 29784146
Cancer. 2020 Aug 15;126(16):3638-3647
pubmed: 32530506
Diabetes Care. 2007 Mar;30(3):707-12
pubmed: 17327345
Atherosclerosis. 2003 Aug;169(2):317-21
pubmed: 12921984
Am J Epidemiol. 2000 Nov 15;152(10):897-907
pubmed: 11092431
Nephrol Dial Transplant. 2016 Feb;31(2):206-13
pubmed: 25550448
Kidney Int. 2017 Apr;91(4):982-988
pubmed: 28187983
Clin J Am Soc Nephrol. 2014 Apr;9(4):690-7
pubmed: 24436478
Clin J Am Soc Nephrol. 2014 Apr;9(4):638-40
pubmed: 24677558
Nat Rev Endocrinol. 2014 May;10(5):293-302
pubmed: 24663222
Nephrol Dial Transplant. 2011 Dec;26(12):3950-4
pubmed: 21441399

Auteurs

Giuseppe Penno (G)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Anna Solini (A)

Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy.

Emanuela Orsi (E)

Diabetes Unit, IRCCS "Cà Granda - Ospedale Maggiore Policlinico" Foundation, Milan, Italy.

Enzo Bonora (E)

Division of Endocrinology, Diabetes and Metabolism, University and Hospital Trust of Verona, Verona, Italy.

Cecilia Fondelli (C)

Diabetes Unit, University of Siena, Siena, Italy.

Roberto Trevisan (R)

Endocrinology and Diabetes Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.

Monica Vedovato (M)

Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy.

Franco Cavalot (F)

Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.

Gianpaolo Zerbini (G)

Complications of Diabetes Unit, Division of Metabolic and Cardiovascular Sciences, San Raffaele Scientific Institute, Milan, Italy.

Olga Lamacchia (O)

Department of Medical Sciences, University of Foggia, Foggia, Italy.

Antonio Nicolucci (A)

Centre for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy.

Giuseppe Pugliese (G)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Via di Grottarossa, 1035-1039, 00189, Rome, Italy. giuseppe.pugliese@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH